AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02881216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Synergy Stent
Description: Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
Study NCT02881216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Currently common drug-eluting stent (DES)
Description: Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
Study NCT01352455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: 5 days per week hemodialysis
Study NCT00005626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan as outlined in treatment arm
Study NCT00991978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-bevacizumab PET
Description: PET-scan with 89Zr-bevacizumab
Study NCT04447222 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04447222 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04447222 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT03673072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
Study NCT03673072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
Study NCT03673072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oncologically radical margin-free (R0) resection
Description: Oncologically radical margin-free (R0) resection
Study NCT03673072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oncologically radical margin-free (R0) resection
Description: Oncologically radical margin-free (R0) resection
Study NCT03673072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Can be selected by Investigator's Choice
Study NCT01681875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes
Study NCT01681875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: very low nicotine content cigarettes
Study NCT06615999 — intervention group
Intervention type: PROCEDURE
Intervention: Simple fracture Tension band wiring
Description: OPS 5-793.27
Study NCT06615999 — intervention group
Intervention type: PROCEDURE
Intervention: Simple fracture locked plate fixation
Description: OPS 5-793.k7
Study NCT03377322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Capsule
Description: Probiotic - one capsule a day for four weeks
Study NCT03377322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo - one capsule a day for four weeks
Study NCT00022854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-injection femoral nerve block
Description: Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
Study NCT00022854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block 60-hour continuous injection
Description: Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
Study NCT00022854 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline (control) injection into femoral nerve envelope
Description: Nerve block bolus with 30 mL saline, followed by continuous saline infusion
Study NCT06615999 — intervention group
Intervention type: PROCEDURE
Intervention: Multi-fragmented tension band wiring
Description: OPS 5-794.17
Study NCT06615999 — intervention group
Intervention type: PROCEDURE
Intervention: Multi-fragmented locked plate fixation
Description: OPS 5-794.k7
Study NCT02735330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: celiac plexus neurolysis using absolute alcohol
Description: celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
Study NCT02735330 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo celiac plexus injection using saline
Description: Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
Study NCT04562792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
Study NCT02735330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frey's procedure
Description: Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
Study NCT03573089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal phosphate target
Description: All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
Study NCT02735330 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Frey's procedure
Description: Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
Study NCT03573089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive phosphate target
Description: This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
Study NCT03615768 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adapalene-Clindamycin Combination Gel
Description: 5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
Study NCT03615768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene Gel
Description: Differin 0.1% Gel, applied nightly for 12 weeks
Study NCT03615768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Gel
Description: Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
Study NCT03682484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-0211
Description: oral
Study NCT03682484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01717274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot saline irrigation
Description: The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
Study NCT01541215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Study NCT01541215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Study NCT01541215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
Study NCT01541215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
Study NCT02906813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Tablets
Description: Tablets
Study NCT02906813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Oral Solution
Description: Oral solution
Study NCT02214563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
Study NCT02214563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Study NCT01226693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 material sparing tablet
Description: oral, 6mg, single dose
Study NCT01226693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 with sodium lauryl sulphate
Description: oral, 6mg, single dose
Study NCT01226693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 without sodium lauryl sulphate
Description: oral, 6mg, single dose
Study NCT00973310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Therapy and EGFR-TKI target therapy
Description: Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
Study NCT03710707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL201
Description: Oral repeating dose
Study NCT03710707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral repeating dose
Study NCT01773239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARA computer-based exercises
Study NCT02285933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
Study NCT02285933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
Study NCT04509050 — intervention group
Intervention type: DRUG
Intervention: Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Description: In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
Study NCT00242892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra coronary measures of pressure
Description: Intra coronary measures of pressure
Study NCT02542215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: Cobiprostone 30 mcg oral spray
Study NCT03391050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Intravenous infusion
Study NCT03391050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Oral administration
Study NCT04594720 — intervention group
Intervention type: OTHER
Intervention: Identification group
Description: papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
Study NCT04594720 — intervention group
Intervention type: OTHER
Intervention: Validation group
Description: papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
Study NCT00804999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clear Care
Description: neutralized Clear Care
Study NCT00804999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReNu
Description: overnight soak in solution
Study NCT00804999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE
Description: overnight soak in solution
Study NCT01182519 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire, blood draw and urine sample
Description: Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
Study NCT02861833 — intervention group
Intervention type: OTHER
Intervention: nursing support
Description: Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
Study NCT02090933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO
Study NCT02090933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02090933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation
Study NCT01655251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Study NCT03133728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Alere Q Testing
Description: Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
Study NCT03887598 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound diagnosis
Description: Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
Study NCT00806962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant/Excipients
Description: intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
Study NCT00806962 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: intranasal, puff of air, 2 doses, 21 days apart
Study NCT00806962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk VLP Vaccine
Description: intranasal, 50mcg, 2 doses--21 days apart
Study NCT00806962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk VLP Vaccine
Description: Intranasal, 100 mcg, 2 doses, 21 days apart
Study NCT00633698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid (niacin)
Description: oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
Study NCT00633698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
Study NCT04313296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)
Description: The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
Study NCT04096651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: gait recordings
Description: gait recordings
Study NCT04096651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: brain magnetic resonance imaging
Description: brain magnetic resonance imaging
Study NCT04096651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oculomotor movement recordings
Description: oculomotor movement recordings
Study NCT04761445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straumann Standard Plus implant and JDental care (JD) Octa implant
Description: Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.
Study NCT03316222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561
Description: Escalating doses to be administered 3 times a week.
Study NCT02394288 — intervention group
Intervention type: PROCEDURE
Intervention: Extremity orthopedic or trauma surgery
Description: hip, leg, shoulder, arm
Study NCT02879773 — intervention group
Intervention type: RADIATION
Intervention: CTPVe
Description: Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
Study NCT02542215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral spray
Study NCT02542215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care - Chemotherapy
Description: Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
Study NCT02542215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care - Chemotherapy
Description: Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
Study NCT02542215 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Care - Radiation
Description: Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
Study NCT02542215 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care - Radiation
Description: Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
Study NCT01903863 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
Study NCT01903863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
Study NCT03231735 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mid frequency ventilation
Description: Mechanical ventilator used at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.